Bethan Deacon
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- COVID-19 Clinical Research Studies 7
- SARS-CoV-2 and COVID-19 Research 5
-
- interferon and immune responses 2
- Journals
- JAMA (6 papers)The Lancet (6 papers)Nature (2 papers)The Lancet Child & Adolescent Health (1 paper)The Lancet Diabetes & Endocrinology (1 paper)
- Partner nations
- AustraliaUnited KingdomIndonesia
In The Last Decade
Bethan Deacon
21 papers receiving 2.4k citations
Bethan Deacon's Hit Papers
Peers
Comparison fields: 5 of 107
- Infectious Diseases 1.4k
- Neurology 480
- Applied Microbiology and Biotechnology 56
- Internal Medicine 85
- Critical Care and Intensive Care Medicine 114
Countries citing papers authored by Bethan Deacon
This map shows the geographic impact of Bethan Deacon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethan Deacon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethan Deacon more than expected).
Fields of papers citing papers by Bethan Deacon
This network shows the impact of papers produced by Bethan Deacon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethan Deacon. The network helps show where Bethan Deacon may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 6 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 7 | 2021 | 163 | |
| 8 | 2022 | 104 | |
| 9 | 2022 | 99 | |
| 10 | 2023 | 83 | |
| 11 | 2021 | 70 | |
| 12 | 2023 | 56 | |
| 13 | 2023 | 45 | |
| 14 | 2024 | 44 | |
| 15 | 2021 | 42 | |
| 16 | 2023 | 34 | |
| 17 | 2023 | 24 | |
| 18 | 2024 | 23 | |
| 19 | 2022 | 8 | |
| 20 | 2024 | 8 |
About Bethan Deacon
Bethan Deacon is a scholar working on Infectious Diseases, Immunology, Epidemiology, Nutrition and Dietetics and Surgery, having authored 21 papers that have together received 2.5k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (5 papers), interferon and immune responses (2 papers), Pneumonia and Respiratory Infections (1 paper), Respiratory viral infections research (1 paper), Sepsis Diagnosis and Treatment (1 paper), Kawasaki Disease and Coronary Complications (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (1.4k citations), Neurology (480 citations), Applied Microbiology and Biotechnology (56 citations), Internal Medicine (85 citations) and Critical Care and Intensive Care Medicine (114 citations). Bethan Deacon has collaborated with scholars based in Australia, United Kingdom and Indonesia. Their work appears in journals such as JAMA, The Lancet, Nature, The Lancet Child & Adolescent Health and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.